Business Wire

AFWERX, the Innovation Arm of the U.S. Air Force, Awards Phase II STTR Contract to Transcend Air

21.6.2022 14:03:00 EEST | Business Wire | Press release

Share

Transcend Air announced today that it was awarded a Phase II Small Business Technology Transfer research and development contract from AFWERX, a Technology Directorate of the Air Force Research Laboratory. Transcend Air, in partnership with Auburn University, will further develop advanced flight control laws for high-speed flight with its Vy 400 vertical takeoff and landing aircraft (VTOL). “Specifically, the high speed flight is referred to as nap-of-the-earth (NOE) flight, which is a demanding regime where an aircraft stays low and follows the contours of terrain to remain undetected,” commented Peter Schmidt, COO of Transcend Air and Principal Investigator.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005201/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Advanced flight control laws developed in simulation (Photo: Business Wire)

Transcend Air is extending its work with Professor Imon Chakraborty and his Vehicle Systems, Dynamics, and Design Laboratory (VSDDL.com) and newly teaming with Professor Ehsan Taheri and his Aero-Astro Computational and Experimental Lab (ACE Lab). Control software will be demonstrated that enables the Vy 400 aircraft to automatically fly nap-of-the-earth in both simulation and real-world flight with 1/5th scale aircraft. The software reduces pilot workload and enables sustained flight in very close proximity to terrain at speeds two to three times faster than helicopters. This capability facilitates the mission of rescuing downed aircrews in one-quarter to one-eighth of the time it currently takes. With that improvement it is projected that nearly double the number of people can be rescued as before.

AFWERX is an arm of the United States Air Force that supports aircraft technology development for commercial and military purposes. VSDDL and ACE Lab are part of the Department of Aerospace Engineering at Auburn University in Auburn, Alabama.

ABOUT TRANSCEND AIR CORPORATION

Transcend Air has designed a family of high speed tiltwing VTOL aircraft. Its Vy 400 is three times faster than helicopters with half the operating costs. Expectations are that the Vy 400 will dominate the VIP transport helicopter segment. It will also enable a new city-center to city-center Aerial Regional Transport service that is up to five times faster door to door, and lower cost as compared with current air travel options. Since 2009, Transcend Air has built and flown 15 prototype VTOL aircraft, giving their patented Vy a long lineage of real-world experience. The Vy 400 will not require new regulatory regimes or air traffic control systems because it utilizes proven technologies that include the General Electric CT7-8 engine and BRS Aerospace whole-aircraft parachute. The Vy 400 brings with it the promise of civil VTOL flight that is within everyone’s reach.

For additional information see www.Transcend.aero

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Peter Schmidt, peter@transcend.aero
t. 781-883-4818

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 12:15:00 EEST | Press release

HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612936893/en/ HUI (HUI:VSE) merges traditional and crypto finance: commences continuous trading in Vienna with leading market maker and announces impending token listing on major global exchange Emmanuelle Deba

Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 10:35:00 EEST | Press release

India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of its farming population. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202606151544

Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 10:00:00 EEST | Press release

Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discovery teams to accelerate decision-making, streamline workflows, and advance programs more efficiently from hit identification through lead optimization. "Drug discovery increasingly requires seamless integration between chemistry and biology," said Michael Dabrowski, Chief Executive Officer of Pelago Bioscience. "By bringing RG Discovery

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera

Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye